Articles

Big Pharma Q1 Growth Insights: Lilly, AbbVie, J&J, AZ Lead the Charge

This article analyzes the recent Q1 growth trends in Big Pharma, focusing on key players and their market implications.

Lilly's Triple-Acting Obesity Drug Achieves Phase 3 Trial Goals

Eli Lilly's triple-acting obesity drug has successfully met its Phase 3 trial goals, marking a significant milestone in obesity treatment. This article explores the implications for the pharmaceutical landscape and investment opportunities.

Dark Times Ahead at the FDA: Implications for Pharma

This article discusses the recent leadership vacuum at the FDA and its potential impact on the pharmaceutical sector. Key insights for business development and investment strategies are provided.

Whoop and FDA: Navigating Controversies in Blood Pressure Monitoring

Whoop is in discussions with the FDA following a warning letter regarding its blood pressure feature. This article explores the implications for the pharmaceutical industry.

Eli Lilly’s Triple-G Drug Achieves Bariatric Surgery-Level Weight Loss

Eli Lilly's 'triple-G' drug demonstrates impressive weight loss results in clinical trials, raising competitive stakes in the obesity treatment market.

Are AI Co-Scientist Tools Useful for Scientists?

This article examines the effectiveness of AI co-scientist tools in scientific research and their implications for the pharmaceutical industry.

Lilly's Triple Agonist: Leading the Charge in Obesity Treatment

Eli Lilly's triple agonist is at the forefront of obesity treatment, showcasing significant potential in late-stage development. This article delves into its implications for the pharmaceutical landscape.

Long-Term Medical Consequences of Retained Bullet Fragments

This article discusses the potential health risks associated with retained bullet fragments, including psychological and physical consequences.

Pfizer's Next-Gen Pneumonia Shot Outperforms Prevnar 20

Pfizer's latest pneumonia vaccine shows superior efficacy compared to Prevnar 20, raising significant investment interest. This article explores the implications for pharma teams and investors.

Parabilis IPO Plans Following Regeneron Deal: What You Need to Know

Parabilis has announced its IPO plans just a day after the Regeneron deal, signaling a surge in listings. This article explores the implications for the pharmaceutical landscape.

Kennedy Appoints Interim Surgeon General: Implications for Pharma

Kennedy's appointment of an interim surgeon general could reshape health policy. This article explores the implications for pharmaceutical teams and investors.

Fetal Gene Therapy: Breaking the Taboo on Embryo Editing

This article examines the recent progress in fetal gene therapy and its implications for the ethical considerations surrounding embryo editing.

Impact of FDA Turnover on Rare Disease Drug Development

Biotech executives and academic experts discuss the implications of FDA turnover on rare disease drug development, highlighting investment risks and opportunities.

Tracking Cellular Disruptions in Type 1 Diabetes: Insights for Pharma

This article explores recent findings on cellular disruptions linked to type 1 diabetes and their implications for pharmaceutical development and investment.

GHO Capital and CBC Group Merge: A New Era in Healthcare Investment

GHO Capital and CBC Group's merger could reshape healthcare investments. Discover the implications for the pharmaceutical industry.

Parabilis Pursues IPO After $800M Funding for Undruggable Targets

Parabilis has raised $800M and is now seeking an IPO to tackle previously undruggable targets, marking a significant shift in its strategy.

Bristol Myers Expands AI Capabilities with Anthropic Partnership

Bristol Myers has deepened its investment in artificial intelligence by partnering with Anthropic. This strategic move aims to enhance its drug development capabilities and competitive edge.

Bristol Myers Squibb Leverages AI for Enhanced R&D Efficiency

Bristol Myers Squibb is adopting Anthropic’s Claude AI to streamline drug R&D processes. This move could significantly impact the pharmaceutical landscape.

How GLP-1s are Transforming Pharma's Consumer Relationships

This article examines the evolving relationship between pharmaceutical companies and consumers, driven by the rise of GLP-1 medications.

Tarsus Partners with John Cena for Demodex Blepharitis Campaign

Tarsus has launched a new campaign featuring John Cena to raise awareness about Demodex blepharitis. This article explores the implications for the pharmaceutical industry.